Unconjugated Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein (Monomer, MALS verified)

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*1101 KRAS (VVVGAGGVGK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M, and VVVGAGGVGK peptide of the KRAS.

Product Specifications

Background

Specifications

Unconjugated Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein is produced by co-expression of HLA and B2M loaded with KRAS peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™), and it is not biotinylated. The protein has a calculated MW of 36.0 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q5S3G3-1 (HLA-A*11:01) & P61769 (B2M) & VVVGAGGVGK

Expression Region

Gly 25 - Thr 305 (HLA-A*11:01) & Ile 21 - Met 119 (B2M) & VVVGAGGVGK peptide

Host

HEK293

Target

HLA-A*1101 & B2M & KRAS (VVVGAGGVGK)

Conjugation

Unconjugated

Tag

C-10xHis & C-Avi

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Unconjugated Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein (Cat. No. HLS-H52E7) at 1 μg/mL (100 μL/well) can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-4 ng/mL (QC tested).